AHF Says US Taxpayers Co-Own Moderna’s COVID-19 VAX Patent

Published : 15 Oct 2020

Drug Name: mRNA-1273

AIDS Healthcare Foundation is known as the recent announcement that Cambridge, Massachusetts-based biotechnology company Moderna has declared that it'll not enforce its patent rights for its COVID-19 immunogen candidate throughout the pandemic if it gets approval from the U.S. Food and Drug Administration (FDA) a “positive development.”

Moderna reportedly received over $1.4 billion from the medical specialty Advanced analysis and Development Authority of the U.S. Department of Health and Human Services (BARDA) to provide a hundred million doses of its COVID-19 immunogen. “AHF agrees with several activists that because the ‘angel investor’ within the immunogen analysis, the U.S. remunerator co-owns the patent,” aforesaid John Hassell, national director of support for AHF. “In the spirit of full transparency, Moderna and BARDA ought to additionally totally disclose the entire price of the project to provide this immunogen for COVID-19 and also the quantity and share of prices provided by the U.S. government.”

AHF additionally calls on Moderna and every one alternative drug firms receiving remunerator funds and taxpayer-funded analysis to form the COVID-19 immunogen on the market to the international community by withholding social control of their patents to form this rescue drugs on the market to wealthy and poor countries equally.

In a connected action, the support cluster Public national aforesaid in an exceedingly press statement that Moderna ought to “… dedicate its technology to the planet Health Organization (WHO) so that the planet will prepare to form vaccines for billions of individuals, instead of allowing immunogen social policy wherever solely loaded countries have immunogen access.”

Source: GlobalData.com